My watch list
my.bionity.com  
Login  

51 Current news about the topic thrombosis

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Abbott's ABSORB Bioresorbable Vascular Scaffold Demonstrates Positive One-Year Safety and Efficacy Results

Clinical Results from 101 Patients Show Low MACE Rate, No Blood Clots and Low Late Loss

04-Apr-2011

Abbott announced positive one-year results from 101 patients enrolled in the second phase of the ABSORB trial evaluating the drug eluting Bioresorbable Vascular Scaffold (BVS) for the treatment of coronary artery disease. These results were presented during the American College of Cardiology's ...

more

New diagnostics company from Berlin

17-Nov-2010

Astra Biotech GmbH is a new company whose core focus is the development of diagnostics for the identification of an individual’s predisposition to disease. With this in mind, Astra Biotech GmbH have produced a significant portfolio of assays in areas such as allergies, genetically associated ...

more

They shall not pass!

Fighting infections with blood clots

05-Aug-2010

The adaptive immune system can recognize and respond specifically to particular infectious agents. But the first line of defence against pathogens is the so-called innate immune system. This system reacts to invaders by initiating unspecific inflammatory responses which attract various types of ...

more

Positive Results from Phase II VTE Prophylaxis Study with TB-402 (Anti-Factor VIII)

Study demonstrates TB-402 superior antithrombotic activity to enoxaparin

12-Jul-2010

ThromboGenics NV and co-development partner BioInvent International announced that the positive results from a Phase II trial of TB-402 (Anti-Factor VIII antibody) were presented at the 21st International Congress on Thrombosis (ICT) in Milan, Italy. TB-402 is a long acting anticoagulant that ...

more

Endotis Pharma presents Phase I clinical trial results for a first-in-class synthetic parenteral neutralizable anticoagulant

09-Jul-2010

Endotis Pharma announced that Phase I clinical trial results for EP217609 were presented at the 21st International Congress on Thrombosis (ICT) in Milan, Italy. EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized by a specific antidote, avidin. EP217609 has a ...

more

Saint Louis University investigators perfect new version of blood-regulator thrombin

Research harnesses enzyme's anti-blood clotting abilities

22-Jun-2010

In research led by Enrico Di Cera, M.D., chair of the department of biochemistry and molecular biology at Saint Louis University School of Medicine, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new ...

more

ThromboGenics and BioInvent Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (TB-402)

07-May-2010

ThromboGenics NV and co-development partner BioInvent International announced positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic ...

more

Bayer achieves strong gains in sales and earnings

Sales advance by 5.3 percent to EUR 8,316 million

03-May-2010

The Bayer Group started off 2010 with strong sales and earnings growth. “Bayer is well on track – and we plan to grow again this year,” said Werner Wenning, Chairman of the Board of Management, when the first-quarter report was published on Thursday. MaterialScience posted a clear recovery in an ...

more

Study finds genes that keep watch on blood clotting time

24-Mar-2010

Scientists have discovered three genes that could shed light on the genetic causes of blood-clotting disorders such as thrombosis and some types of stroke. Researchers at the University of Edinburgh have discovered that the three genes make a substantial contribution to how long it takes blood to ...

more

Big pharmaceutical struggles to benefit from increased CVD drug usage

04-Mar-2010

Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. New research by the independent business analyst predicts that the CVD pharma market will grow from $99bn in 2008 to $107bn in ...

more

Page 2 From 6
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE